BUZZ-GRI Bio climbs on lung disease drug trial data

Reuters09-11
BUZZ-GRI Bio climbs on lung disease drug trial data

** Shares of drug developer GRI Bio GRI.O rise 52% to $2.35 premarket

** Co says its experimental lung disease drug, GRI-0621, showed no decline in lung function after six weeks of treatment in an ongoing mid-stage trial

** Co is testing the drug for the treatment of idiopathic pulmonary fibrosis, a chronic lung disease where scar tissue builds up in the lungs, making it harder to breathe over time

** The drug was tested in 24 patients and showed no worsening in forced vital capacity, a key measure of lung function

** An independent monitoring committee recommended the study continue as planned

** As of last close, stock down 89% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment